Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Aspirin  COVID-19 treatment studies for Aspirin  C19 studies: Aspirin  Aspirin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 71% Improvement Relative Risk Santoro et al. Aspirin for COVID-19 LATE TREATMENT Is late treatment with aspirin beneficial for COVID-19? Retrospective 7,824 patients in multiple countries Lower mortality with aspirin (p<0.000001) Santoro et al., European Heart J., doi:10.1093/eurheartj/ehab724.3002 Favors aspirin Favors control
Antiplatelet therapy and outcome in patients with COVID-19. Results from a multi-center international prospective registry (HOPE-COVID19)
Santoro et al., European Heart Journal, doi:10.1093/eurheartj/ehab724.3002
Santoro et al., Antiplatelet therapy and outcome in patients with COVID-19. Results from a multi-center international.., European Heart Journal, doi:10.1093/eurheartj/ehab724.3002
Oct 2021   Source   PDF  
  All Studies   Meta
Retrospective database analysis of 7,824 patients in the HOPE-COVID19 registry, 730 receiving antiplatelet therapy including aspirin, showing lower mortality with treatment. Authors do not provide results restricted to aspirin.
risk of death, 71.0% lower, RR 0.29, p < 0.001, treatment 730, control 7,094, antiplatelet therapy, multivariable.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Santoro et al., 14 Oct 2021, retrospective, multiple countries, peer-reviewed, 6 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperAspirinAll
Abstract: 3002 Pharmacology and Pharmacotherapy – Cardiovascular Pharmacotherapy, Antiplatelet Drugs Antiplatelet therapy and outcome in patients with COVID-19. Results from a multi-center international prospective registry (HOPE-COVID19) F. Santoro 1 , E. Vitale 1 , I. Nunez Gil 2 , F. Guerra 3 , I. El-Battrawy 4 , N.D. Brunetti 1 1 University of Foggia, Department of Cardiology, Foggia, Italy; 2 Hospital Clinico San Carlos, Deparment of Cardiology, Madrid, Spain; 3 University Hospital Riuniti of Ancona, Deparment of Cardiology, Ancona, Italy; 4 University Medical Centre of Mannheim, Deparment of Cardiology, Mannheim, Germany Funding Acknowledgement: Type of funding sources: None. Patients treated with APT showed no differences in terms of in-hospital mortality (18% vs 19%, p=0.64, Log Rank p=0.23), need of invasive ventilation (8.7% vs 8.5%, p=0.88) and bleeding (2.1% vs 2.4%, p=0.43); However, after excluding patients treated only with anticoagulation, APT was associated with lower mortality rates (Log Rank p<0.01, relative risk 0.79, 95% CI 0.70–0.94) (Figure 1). At multivariable analysis including age, gender, diabetes, hypertension, respiratory failure, pre-hospital therapy with antiplatelet drugs, in-hospital APT, and anticoagulation therapy, in-hospital APT was associated with a lower mortality risk (relative risk 0.29, 95% CI 0.22–0.38, p<0.001). Conclusions: APT during hospitalization for COVID-19 could be associated with lower mortality risk without increased risk of bleeding. Randomized trials are needed to confirm these preliminary data. Figure 1 ESC Congress 2021 – The Digital Experience 27– 30 August 2021 Background: No standard therapy is currently recommended for Coronavirus-19 disease (COVID-19). Autopsy studies showed high prevalence of platelet-fibrin rich micro-thrombi in several organs. Aim of the study was to evaluate safety and efficacy of antiplatelet therapy (APT) in COVID-19 hospitalized patients and its impact on survival. Methods: 7824 consecutive patients with COVID-19 were enrolled in a multicenter-international prospective registry (HOPE-COVID19). Clinical data and in-hospital complications were recorded. AP regimen, including aspirin and other antiplatelet drugs, was obtained for each patient. Results: During hospitalization 730 (9.3%) patients received AP drugs with single (93%, n=680) or dual APT (7%, n=50). Patients treated with APT were older (73±12 vs 62±17 years, p<0.01), more frequently male (70% vs 64%, p<0.01) and had higher prevalence of diabetes (39.5% vs 17%, p<0.01).
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop